Case Details
- Citation: [2012] SGHC 253
- Case Title: Novartis AG and another v Ranbaxy (Malaysia) Sdn Bhd
- Court: High Court of the Republic of Singapore
- Date of Decision: 28 December 2012
- Case Number: Suit No 150 of 2011
- Tribunal/Coram: High Court; Lee Seiu Kin J
- Judgment Reserved: Yes
- Plaintiff/Applicant: Novartis AG and another
- Defendant/Respondent: Ranbaxy (Malaysia) Sdn Bhd
- Patent in Issue: Patent No SG120119 (“Patent”)
- Application Type: Application for leave to amend patent claims
- Key Procedural Basis: O 87A r 11(6) of the Rules of Court (Cap 322, R 5, 2006 Rev Ed)
- Key Substantive Basis: s 83 of the Patents Act (Cap 221, 2005 Rev Ed) (“the Act”)
- Statutory Provision Governing Limits on Amendment: s 84(3)(a) of the Act (no additional matter)
- Other Statute Mentioned (context): Medicines Act (Cap 176, 1985 Rev Ed), s 12A(3)(a)
- Legal Area: Patents and inventions; pharmaceutical patent litigation
- Counsel for Plaintiffs: Tony Yeo, D K Rozalynne PG Dato Asmali and Dora Tay (Drew and Napier LLC)
- Counsel for Defendant: Daniel Koh (Eldan Law LLP) (instructed) and Andrew Quirk (foreign counsel from Mirandah Law LLP)
- Judgment Length: 19 pages, 10,337 words
- Cases Cited (as provided): [2012] SGHC 253 (self-citation in metadata); Bonzel (T) and anr v Intervention Limited and anr (No 3) [1991] RPC 553; FE Global Electronics Pte Ltd v Trek Technology (Singapore) Pte Ltd [2006] 1 SLR(R) 874; Martek Biosciences Corp v Cargill International Trading Pte Ltd [2011] 4 SLR 429; Main-Line Corporate Holdings Ltd v DBS Bank Ltd [2012] 4 SLR 147; European Central Bank v Document Security Systems Incorporated [2007] EWHC 600; DSM NV’s Patent [2001] RPC 25; G1/93 (EPO Enlarged Board of Appeal) Advanced Semiconductor Products
Summary
Novartis AG and its exclusive licensee sought leave to amend the claims of their Singapore patent (Patent No SG120119) in ongoing infringement proceedings against Ranbaxy (Malaysia) Sdn Bhd. The dispute arose in the context of Singapore’s regulatory “notice” mechanism for pharmaceutical product licences: Ranbaxy applied to import and market products in Singapore that the plaintiffs alleged would infringe the patent. The plaintiffs commenced suit and, in parallel, applied to amend their patent claims to improve clarity, reduce the number of claims, and better distinguish the claimed subject matter from prior art relied upon by Ranbaxy.
The High Court (Lee Seiu Kin J) granted leave only to the extent permitted by the Patents Act’s strict limits on amendments. The central legal question was whether the proposed amendments would “add matter” to the patent specification as filed, contrary to s 84(3)(a) of the Patents Act. Applying the established “Bonzel” test, the court construed both the original application and the proposed amended specification through the eyes of the skilled addressee, compared the disclosures, and asked whether any relevant subject matter had been added unless it was clearly and unambiguously disclosed in the application as filed.
What Were the Facts of This Case?
Novartis AG was the registered proprietor of the patent in suit, and the second plaintiff was its exclusive licensee. Ranbaxy (Malaysia) Sdn Bhd, a pharmaceutical company, intended to import for marketing in Singapore products known as “Starval Tablets”. The plaintiffs alleged that the compositions and intended use of Ranbaxy’s products fell within the scope of their Singapore patent.
The regulatory background was critical. Under s 12A(3)(a) of the Medicines Act, Ranbaxy was obliged to serve notices on the patent proprietor when applying to the Health Sciences Authority for product licences. The notices were designed to inform the patent proprietor that the proposed imported products could potentially infringe the patent, and to prompt the proprietor to commence court proceedings within a specified time window. The plaintiffs received the requisite notices and commenced the suit shortly thereafter, seeking declarations of infringement if the licences were granted and the products imported and marketed in Singapore.
In its defence and counterclaim, Ranbaxy challenged the validity of the patent. The invalidity argument was anchored on anticipation by prior art. Two prior art documents were relied upon, referred to in the judgment as DA1 and DA2. Although the full details of DA1 and DA2 are not reproduced in the extract provided, the thrust of the case was that the plaintiffs’ original claim language was vulnerable to being read as covering subject matter already disclosed in those references.
To address these concerns, the plaintiffs sought to amend the patent claims. Their stated objectives were to “enhance clarity”, “highlight the inventive contributions”, reduce the number of claims, and further distinguish the claims from the matter disclosed in the prior art references cited by Ranbaxy. At the hearing, counsel agreed that the essential dispute concerned whether amendments to claims 1 and 5 were permissible; amendments to other claims were consequential to those changes.
What Were the Key Legal Issues?
The principal legal issue was whether the proposed amendments to the patent claims would contravene s 84(3)(a) of the Patents Act by resulting in the specification disclosing “additional matter”. In other words, the court had to determine whether the amended claims introduced subject matter that was not clearly and unambiguously disclosed in the patent application as filed.
A related issue, though not the focus of the extract, is that amendments in patent litigation are constrained not only by the “no additional matter” rule but also by the prohibition on amendments that extend protection (s 84(3)(b)). In this application, the extract indicates that only s 84(3)(a) was germane. Accordingly, the court’s analysis concentrated on the disclosure-comparison exercise rather than on whether the scope of protection was broadened.
Finally, the court had to apply the correct legal test for “added matter” in the Singapore context. The judgment emphasised that the applicable test was that laid down in Bonzel (T) and anr v Intervention Limited and anr (No 3) [1991] RPC 553, which has been endorsed in multiple local decisions. The court therefore had to apply that test to the specific amendments proposed for claims 1 and 5.
How Did the Court Analyse the Issues?
The court began by setting out the statutory framework. The plaintiffs’ application was brought under s 83(1) of the Patents Act, which gives the court discretion to allow amendment of a patent specification in proceedings where validity is in issue. However, that discretion is limited by s 84(3). In this case, the relevant limitation was s 84(3)(a): no amendment is allowed if it results in the specification disclosing additional matter.
To operationalise s 84(3)(a), the court adopted the Bonzel test. The Bonzel formulation requires a three-step task. First, the court must ascertain what is disclosed in the application as filed, both explicitly and implicitly, through the eyes of the skilled addressee. Second, the court must do the same for the patent as granted (or, in the amendment context, the amended specification). Third, the court must compare the two disclosures and decide whether any subject matter relevant to the invention has been added, with a strict approach: subject matter will be added unless it is clearly and unambiguously disclosed in the application as filed.
The High Court then reinforced that the Bonzel test is not an obviousness test. The patentee is not permitted to add matter by amendment merely because the added feature might have been obvious to the skilled person. Instead, the question is whether the added feature is already part of the disclosure in the application as filed, either expressly or implicitly, and whether it is “clearly and unambiguously” derivable from that disclosure.
In elaborating the Bonzel approach, the court referred to European Central Bank v Document Security Systems Incorporated [2007] EWHC 600. That decision emphasises that the court must construe both the original application and the amended specification, that the skilled addressee has the benefit of common general knowledge, and that the comparison is strict. It also clarifies that implicit disclosure can include what the skilled person would take for granted, but it does not permit the patentee to improve its position by adding technical features that were not disclosed. The court also referenced the underlying rationale reflected in EPO jurisprudence (including G1/93), namely that an applicant should not be allowed to gain an unwarranted advantage by adding subject matter not disclosed in the original application, which could undermine legal security for third parties relying on the original disclosure.
Applying these principles to the pharmaceutical context, the court noted that the dispute was narrower than the overall amendment application. The parties agreed that the key question was whether amendments to claims 1 and 5 were permissible, and that other amendments were consequential. The extract also records several matters that were not disputed: (a) valsartan is an active agent for which a separate patent subsists; (b) microcrystalline cellulose is an excipient/exigent that improves performance of valsartan when used in a certain dosage; (c) crospovidone is a disintegrant; and (d) the patent relates to how valsartan is delivered and absorbed, rather than to the compound of valsartan itself.
While the extract does not reproduce the full reasoning on the specific claim language changes, it does show the nature of the proposed amendments. The amended claims focused on a compressed tablet formulation comprising valsartan in free form as the only active agent, together with specified ranges and proportions of microcrystalline cellulose and crospovidone. Claim 1 and claim 5 (as proposed) appear to adjust quantitative ranges for those excipients and/or the ratio between valsartan and microcrystalline cellulose. The court’s analysis would therefore have turned on whether those specific numerical ranges and compositional limitations were already disclosed in the application as filed, either explicitly or implicitly, and whether the amendments merely clarified or reorganised what was already present rather than introducing new technical information.
In this kind of amendment dispute, the “added matter” analysis typically requires careful attention to whether the original specification disclosed the same ranges, whether it disclosed the relevant selection from a broader list, and whether the amended claim features were directly and unambiguously derivable from the original disclosure. The court’s insistence on the strict Bonzel standard indicates that even if the amended ranges might be considered “obvious” or “reasonable” selections, they would still be impermissible if they were not clearly and unambiguously disclosed in the application as filed.
What Was the Outcome?
The High Court granted leave to amend in accordance with the Patents Act’s constraints, but the extract indicates that the court treated claims 1 and 5 as the decisive battleground. The outcome therefore depended on whether the proposed amendments to those claims satisfied the “no additional matter” requirement under s 84(3)(a). Where amendments were found to introduce subject matter not clearly and unambiguously disclosed in the application as filed, they would be refused; where amendments were consistent with the original disclosure, leave would be granted.
Practically, the decision is significant for ongoing infringement proceedings because amended claims can affect the scope of the infringement analysis and the validity contest. The court’s approach underscores that amendment is not a mechanism to “fix” weaknesses by adding new technical limitations unless those limitations are already supported by the original disclosure.
Why Does This Case Matter?
This decision is a useful Singapore authority on the strict approach to patent claim amendments under s 84(3)(a) of the Patents Act. It confirms that the Bonzel test—adopted and endorsed in multiple local cases—governs the “added matter” inquiry. For practitioners, the case reinforces that the court will not permit amendments that improve the patentee’s position by introducing features that are not clearly and unambiguously disclosed in the application as filed.
In pharmaceutical patent litigation, where claim amendments often involve reformulating dosage forms, excipient selection, and numerical ranges, this case highlights the importance of drafting and disclosure strategy at the application stage. If the original specification does not disclose the specific compositional ranges later sought in amended claims, the patentee may be unable to obtain leave to amend even if the amended claim is narrower or more targeted against prior art.
From a litigation perspective, the decision also illustrates how amendment applications intersect with regulatory patent notice regimes and infringement proceedings. The Medicines Act notice system accelerates the timing of patent disputes by requiring patent proprietors to act within a defined period after receiving notice of potential infringement. In that compressed procedural environment, amendment applications may be used to refine claims to withstand validity challenges, but they remain constrained by the statutory “no additional matter” rule.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), s 83(1)
- Patents Act (Cap 221, 2005 Rev Ed), s 84(3)(a)
- Rules of Court (Cap 322, R 5, 2006 Rev Ed), O 87A r 11(6)
- Medicines Act (Cap 176, 1985 Rev Ed), s 12A(3)(a)
Cases Cited
- Bonzel (T) and anr v Intervention Limited and anr (No 3) [1991] RPC 553
- FE Global Electronics Pte Ltd and others v Trek Technology (Singapore) Pte Ltd and another appeal [2006] 1 SLR(R) 874
- Martek Biosciences Corp v Cargill International Trading Pte Ltd [2011] 4 SLR 429
- Main-Line Corporate Holdings Ltd v DBS Bank Ltd [2012] 4 SLR 147
- European Central Bank v Document Security Systems Incorporated [2007] EWHC 600
- DSM NV’s Patent [2001] RPC 25
- G1/93, Advanced Semiconductor Products (EPO Enlarged Board of Appeal)
Source Documents
This article analyses [2012] SGHC 253 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.